Abstract:Purpose: Tryptophan metabolism is involved in the etiology and exacerbation of depressive disorders. Kai-Xin-San (KXS), a traditional Chinese medicine formula, has been widely used to treat depression and modulate serotonin simultaneously, but how it regulates depressive-like behavior by shifting the balance of the tryptophan-serotonin metabolism and kynurenine pathway remains vague.Patients and Methods: Ten participants with mild to moderate depression treated with KXS (KXS preparation) were analyzed in this study. Depression rating scale score and the concentration of serum tryptophan, 5-hydroxytryptophan and kynurenine was measured at baseline and the endpoint of KXS treatment. To explore the specific regulatory mechanism of KXS in tryptophan metabolism, the chronic restraint stress (CRS) was used to induce depressive-like syndrome in rats and the hippocampus level of tryptophan, 5-hydroxytryptophan, kynurenine with downstream metabolites (kynurenic acid, quinolinic acid) and key enzymes (indoleamine 2,3-dioxygenase, kynurenine 3-monooxygenase, kynurenine aminotransferase) were analyzed by liquid chromatography-electros pray ionization tandem mass spectrometry, high performance liquid chromatography and enzyme-linked immunosorbent assay respectively. Results: KXS significantly decreased depression rating scale scores and increased the serum tryptophan and kynurenine concentration in depressive patients compared to baseline. Also, it alleviated the depressive behavior in CRS rats obviously. Comparing with CRS group, KXS increased tryptophan, 5-hydroxytryptophan, kynurenine level in rat hippocampus. Furthermore, in kynurenine pathway, KXS decreased the expression of indoleamine 2,3-dioxygenase, increased kynurenic acid by upregulating the expression of kynurenine aminotransferase while decreased quinolinic acid level in hippocampus, which suggested that KXS more favored improving serotonin pathway, and neuroprotective kynurenic acid branch in the tryptophan metabolism.Conclusion: This is the first tryptophan metabolomic study of patients with depression undergoing KXS treatment. Combining these clinical results with CRS induced rat model studies, it verified that KXS achieves an excellent antidepressant effect and balances tryptophan-kynurenine metabolic pathways by regulating some key metabolic products and enzymes.

The kynurenine pathway in major depressive disorder under different disease states: A systematic review and meta-analysis

Involvement of Kynurenine Metabolism in Bipolar Disorder: an Updated Review

KXS Balances the Tryptophan Metabolism in Mild to Moderate Depressed Patients and Chronic Restraint Stress Induced Depressive Rats.

The kynurenine pathway in major depressive disorder, bipolar disorder, and schizophrenia: a meta-analysis of 101 studies

Kynurenines are altered in the brain in depression, in a subgroup dependent manner: Implications for targeted treatment approaches

Dysregulation of Kynurenine Pathway and Potential Dynamic Changes of Kynurenine in Schizophrenia: A Systematic Review and Meta-Analysis

The role and mechanism of tryptophan – kynurenine metabolic pathway in depression

Serum neuroactive metabolites of the tryptophan pathway in patients with acute phase of affective disorders

Dysbiosis of the Gut Microbiota and Kynurenine (Kyn) Pathway Activity as Potential Biomarkers in Patients with Major Depressive Disorder

Kynurenines Increase MRS Metabolites in Basal Ganglia and Decrease Resting State Connectivity in Frontostriatal Reward Circuitry in Depression

The Tryptophan Catabolite or Kynurenine Pathway in a Major Depressive Episode with Melancholia, Psychotic Features and Suicidal Behaviors: A Systematic Review and Meta-Analysis

Kynurenic acid is a potential overlapped biomarker between diagnosis and treatment response for depression from metabolome analysis

Frontostriatal Circuitry and the Tryptophan Kynurenine Pathway in Major Psychiatric Disorders

Unlocking the Potential of the 3-Hydroxykynurenine/kynurenic Acid Ratio: a Promising Biomarker in Adolescent Major Depressive Disorder

Kynurenines Increase MRS Metabolites in Basal Ganglia and Decrease Resting-State Connectivity in Frontostriatal Reward Circuitry in Depression.

The Tryptophan Catabolite or Kynurenine Pathway's Role in Major Depression

A study of tryptophan, kynurenine and serotonin transporter in first-episode drug-naïve major depressive disorder

Regulation of proinflammatory monocyte activation by the kynurenine-AhR axis underlies immunometabolic control of depressive behavior in mice.

Changes in tryptophan breakdown associated with response to multimodal treatment in depression

Gene expression of kynurenine pathway enzymes in depression and following electroconvulsive therapy

Neurobiological mechanisms in the kynurenine pathway and major depressive disorder